Cite
HARVARD Citation
Leleu, X. et al. (2021). Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leukemia & lymphoma. 62 (2), pp. 358-367. [Online].